רווחיות גולמית: X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals leads in the therapy of rare immune pathologies, developing a high-margin orphan drug segment and implementing XOLREMDI. Gross margin stability confirms the effectiveness of the core product, with the indicator holding at 80.90. Active sales are accelerating revenue growth, while production cycles have been fully transferred to external contractors, creating a significant dependence on outsourcing partners.
פילוחי נתונים אנליטיים מרוכזים עבור X4 Pharmaceuticals (XFOR)

The gross margin of X4 Pharmaceuticals (XFOR) determines the share of profit from mavorixafor sales after deducting direct production costs, reflecting the fundamental efficiency of the therapy for rare immune diseases. Analyzing the gross margin level allows for the filtering of market noise and an assessment of the company's ability to convert an innovative drug into actual cash flow, confirming the long-term financial sustainability of the business.